@article{365ebed5c7174b918cbc095811edb8b0,
title = "Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study",
abstract = "Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.",
keywords = "NSCLC, T790M, afatinib, osimertinib, sequential",
author = "Hochmair, {Maximilian J.} and Alessandro Morabito and Desiree Hao and Yang, {Cheng Ta} and Soo, {Ross A.} and Yang, {James C.H.} and Rasim Gucalp and Balazs Halmos and Lara Wang and Angela M{\"a}rten and Tanja Cufer",
note = "Funding Information: This study was supported by Boehringer Ingelheim. MJ Hochmair reports personal fees from Speakers honorarium from Boehringer Ingelheim, AstraZeneca and Roche. A Morabito has received honoraria from Boehringer Ingelheim, Roche, AstraZeneca, Pfizer, MSD and Bristol-Myers Squibb. D Hao reports research funding and consultancy from Boehringer Ingelheim and AstraZeneca. RA Soo reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, personal fees from BMS, Boehringer Ingelheim, Celgene, Lilly, Merck, Novartis, Pfizer, Roche, Taiho, Takeda and Yuhan. JC-H Yang reports personal fees from Boehringer Ingelheim, Eli Lilly, Roche/Genentech, Chugai, Astellas, MSD, Merck Serono, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, Bristol-Myers Squibb, Ono Pharmaceuticals, Daiichi Sankyo, AstraZeneca, Hansoh Pharmaceuticals and Takeda Pharmaceuticals. B Halmos reports grants and personal fees from Boehringer Ingelheim, AstraZeneca, Pfizer, Novartis and Takeda, personal fees from Genentech/Roche, and grants from Merck. L Wang and A M{\"a}rten report employment with Boehringer Ingelheim. T Cufer reports consultancy and honoraria from AstraZeneca, Roche, Pfizer, MSD, Bristol-Myers Squibb, and Boehringer Ingelheim. C-T Yang and R Gucalp report no competing interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2019 Maximilian J Hochmair.",
year = "2019",
doi = "10.2217/fon-2019-0346",
language = "English (US)",
volume = "15",
pages = "2905--2914",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "25",
}
